Federal watchdog bashes controversial drug discount program for lax oversight

Published



The Government Accountability Office found major oversight problems with a controversial drug discount program for safety net hospitals.

The federal watchdog report requested by the House Energy and Commerce Committee comes amid increasing scrutiny of the program that mandates drug makers to provide discounts to safety net hospitals that provide care to low-income patients. The pharmaceutical industry has argued that the discount program, goes by the name 340B, has run rampant due to rapid expansion, while hospital groups charge that efforts to cut it will imperil care for low-income patients.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.